The U.S. Food and Drug Administration (FDA) has approved an expanded use for leucovorin calcium tablets (Wellcovorin, GlaxoSmithKline) to treat cerebral folate transport deficiency (CFD), a rare genetic condition impacting the brain’s ability to utilize folate, a crucial vitamin for neurological health. This marks the first approved treatment specifically for CFD, offering potential hope for individuals, including children, affected by this debilitating disorder.
The approval, initiated on September 22, 2025, and formalized through a previously withdrawn modern drug application, addresses a condition often presenting with developmental delays and autistic features, such as challenges with social communication, sensory processing difficulties, and repetitive behaviors. CFD can also manifest as seizures and problems with movement, and coordination. The FDA’s decision is based on a systematic analysis of published literature spanning 2009-2024, including patient-level data from case reports and mechanistic studies, demonstrating leucovorin calcium’s potential benefit for those suffering from CFD.
Understanding Cerebral Folate Deficiency
Cerebral folate deficiency is a neurological disorder caused by defects in the folate receptor 1 gene (CFD-FOLR1). This genetic variant impairs the transport of folate into the cerebrospinal fluid, which is essential for proper brain development and function. The condition is considered ultra-rare, making research and treatment development particularly challenging. The FDA approval specifically targets patients with a confirmed variant in the folate receptor 1 gene. As reported by HCP Live, this targeted approach ensures the treatment is directed towards those most likely to benefit.
A Shift in Approach: Repurposing Existing Drugs
This approval represents a notable shift in the FDA’s approach to addressing rare diseases and unmet medical needs. Rather than requiring a traditional, lengthy clinical trial, the agency leveraged existing data and scientific literature to expedite access to a potentially life-changing treatment. “We have witnessed a tragic four-fold increase in autism over two decades,” said FDA Commissioner Marty Makary, M.D., M.P.H. according to an FDA press release. “Children are suffering and deserve access to potential treatments that have shown promise. We are using gold standard science and common sense to deliver for the American people.”
George Tidmarsh, M.D., Ph.D., Director of the FDA’s Center for Drug Evaluation and Research, emphasized the agency’s commitment to identifying opportunities to repurpose existing drugs for chronic diseases. This effort reflects the FDA’s commitment to identify opportunities to repurpose drugs to treat chronic diseases.” GSK, the manufacturer of Wellcovorin, has agreed to collaborate with the FDA to update the drug’s labeling to reflect this new indication.
What’s Next for Wellcovorin and CFD Patients?
The FDA is currently working with GSK to finalize the necessary labeling updates for Wellcovorin, ensuring healthcare providers have the essential information needed for safe and effective use in both adult and pediatric patients with CFD. The Federal Register notice details the approval of the previously withdrawn new drug application, highlighting the agency’s commitment to addressing this rare condition. While this approval is a significant step forward, ongoing research is crucial to further understand the long-term effects of leucovorin calcium treatment and to explore potential improvements in diagnosis and management of CFD.
This approval offers a beacon of hope for individuals and families affected by cerebral folate deficiency. The FDA’s innovative approach to drug approval underscores its dedication to addressing unmet medical needs and delivering potential treatments to those who need them most.
Have you or a loved one been affected by cerebral folate deficiency? Share your thoughts and experiences in the comments below. Please also share this article to help raise awareness about this rare condition.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
